BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 11358827)

  • 1. Interleukin (IL)-12 and IL-12 gene transfer up-regulate Fas expression in human osteosarcoma and breast cancer cells.
    Lafleur EA; Jia SF; Worth LL; Zhou Z; Owen-Schaub LB; Kleinerman ES
    Cancer Res; 2001 May; 61(10):4066-71. PubMed ID: 11358827
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interleukin-12 up-regulates Fas expression in human osteosarcoma and Ewing's sarcoma cells by enhancing its promoter activity.
    Zhou Z; Lafleur EA; Koshkina NV; Worth LL; Lester MS; Kleinerman ES
    Mol Cancer Res; 2005 Dec; 3(12):685-91. PubMed ID: 16380506
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential antitumor effects of administration of recombinant IL-18 or recombinant IL-12 are mediated primarily by Fas-Fas ligand- and perforin-induced tumor apoptosis, respectively.
    Hashimoto W; Osaki T; Okamura H; Robbins PD; Kurimoto M; Nagata S; Lotze MT; Tahara H
    J Immunol; 1999 Jul; 163(2):583-9. PubMed ID: 10395644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased Fas expression reduces the metastatic potential of human osteosarcoma cells.
    Lafleur EA; Koshkina NV; Stewart J; Jia SF; Worth LL; Duan X; Kleinerman ES
    Clin Cancer Res; 2004 Dec; 10(23):8114-9. PubMed ID: 15585647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IL-10 protects mouse intestinal epithelial cells from Fas-induced apoptosis via modulating Fas expression and altering caspase-8 and FLIP expression.
    Bharhani MS; Borojevic R; Basak S; Ho E; Zhou P; Croitoru K
    Am J Physiol Gastrointest Liver Physiol; 2006 Nov; 291(5):G820-9. PubMed ID: 17030898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IFN-γ enhances HOS and U2OS cell lines susceptibility to γδ T cell-mediated killing through the Fas/Fas ligand pathway.
    Li Z; Xu Q; Peng H; Cheng R; Sun Z; Ye Z
    Int Immunopharmacol; 2011 Apr; 11(4):496-503. PubMed ID: 21238618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel bystander effect involving tumor cell-derived Fas and FasL interactions following Ad.HSV-tk and Ad.mIL-12 gene therapies in experimental prostate cancer.
    Hall SJ; Canfield SE; Yan Y; Hassen W; Selleck WA; Chen SH
    Gene Ther; 2002 Apr; 9(8):511-7. PubMed ID: 11948376
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intranasal therapy with an adenoviral vector containing the murine interleukin-12 gene eradicates osteosarcoma lung metastases.
    Worth LL; Jia SF; Zhou Z; Chen L; Kleinerman ES
    Clin Cancer Res; 2000 Sep; 6(9):3713-8. PubMed ID: 10999765
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interferon-gamma sensitizes osteosarcoma cells to Fas-induced apoptosis by up-regulating Fas receptors and caspase-8.
    Inaba H; Glibetic M; Buck S; Ravindranath Y; Kaplan J
    Pediatr Blood Cancer; 2004 Dec; 43(7):729-36. PubMed ID: 15390286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of Fas (CD95) expression and Fas-mediated apoptosis by oncogenic Ras.
    Fenton RG; Hixon JA; Wright PW; Brooks AD; Sayers TJ
    Cancer Res; 1998 Aug; 58(15):3391-400. PubMed ID: 9699671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retinoic acid induces expression of the interleukin-1beta gene in cultured normal human mammary epithelial cells and in human breast carcinoma lines.
    Liu L; Gudas LJ
    J Cell Physiol; 2002 Nov; 193(2):244-52. PubMed ID: 12385002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fas cross-linking mimics the inhibitory effect of anti-CD3 on IL-3-induced histamine and cytokine production by murine myeloid spleen cell precursors.
    Ben Amor A; Schneider E; Arnould A; Machavoine F; Dy M
    Exp Hematol; 1998 Aug; 26(9):903-9. PubMed ID: 9694512
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fas expression and function in normal and malignant breast cell lines.
    Keane MM; Ettenberg SA; Lowrey GA; Russell EK; Lipkowitz S
    Cancer Res; 1996 Oct; 56(20):4791-8. PubMed ID: 8841000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of Fas/FasL in the metastatic potential of osteosarcoma and targeting this pathway for the treatment of osteosarcoma lung metastases.
    Gordon N; Kleinerman ES
    Cancer Treat Res; 2009; 152():497-508. PubMed ID: 20213411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recruitment of hepatic NK cells by IL-12 is dependent on IFN-gamma and VCAM-1 and is rapidly down-regulated by a mechanism involving T cells and expression of Fas.
    Fogler WE; Volker K; Watanabe M; Wigginton JM; Roessler P; Brunda MJ; Ortaldo JR; Wiltrout RH
    J Immunol; 1998 Dec; 161(11):6014-21. PubMed ID: 9834083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intranasal interleukin-12 gene therapy enhanced the activity of ifosfamide against osteosarcoma lung metastases.
    Duan X; Jia SF; Koshkina N; Kleinerman ES
    Cancer; 2006 Mar; 106(6):1382-8. PubMed ID: 16453328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of the Fas-FasL signaling pathway by MDA-7/IL-24 kills human ovarian cancer cells.
    Gopalan B; Litvak A; Sharma S; Mhashilkar AM; Chada S; Ramesh R
    Cancer Res; 2005 Apr; 65(8):3017-24. PubMed ID: 15833826
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB.
    Menendez JA; Mehmi I; Atlas E; Colomer R; Lupu R
    Int J Oncol; 2004 Mar; 24(3):591-608. PubMed ID: 14767544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy by gene transfer with plasmids encoding IL-12/IL-18 is superior to IL-23/IL-18 gene transfer in a rat osteosarcoma model.
    Liebau C; Roesel C; Schmidt S; Karreman C; Prisack JB; Bojar H; Merk H; Wolfram N; Baltzer AW
    Anticancer Res; 2004; 24(5A):2861-7. PubMed ID: 15517889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor-derived interleukin-8 stimulates osteolysis independent of the receptor activator of nuclear factor-kappaB ligand pathway.
    Bendre MS; Margulies AG; Walser B; Akel NS; Bhattacharrya S; Skinner RA; Swain F; Ramani V; Mohammad KS; Wessner LL; Martinez A; Guise TA; Chirgwin JM; Gaddy D; Suva LJ
    Cancer Res; 2005 Dec; 65(23):11001-9. PubMed ID: 16322249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.